Skip to main content
. 2020 Jul 24;11(7):571. doi: 10.1038/s41419-020-02793-3

Fig. 4. OSBPL3 upregulation activates RAS signaling pathway in CRC.

Fig. 4

a GO and KEGG analysis of genes with co-expression characteristics of OSBPL3 in human tumors, including lung, breast and colorectal cancers. b GSEA plot showed that high expression of OSBPL3 was positively correlated with the RAC1 pathway in published CRC patient gene expression profiles (GSE13067, n = 74, and GSE13294, n = 155). c Western blot analysis in indicated cells of protein products of RAS signaling pathway involved genes. d Confocal laser scanning microscopy analysis of the actin cytoskeletal remodeling of CRC cells with OSBPL3 overexpression. e RKO/ OSBPL3 cells were treated with the R-RAS inhibitor GGTI-2133 (38 nM) or DMSO for 24 h, then harvested to examine the expression levels of the indicated proteins by Western blotting. f–h RKO/ OSBPL3 cell proliferation was determined by MTT (f), colony formation (g) and soft agar assays (h) after treatment with GGTI-2133 or DMSO. i, j RKO/ OSBPL3 cell invasion and metastasis was determined by transwell (i) and 3D morphogenesis (j) after treatment with GGTI-2133 or DMSO. Error bars represent mean ± SD from 3 independent experiments; **p < 0.01.